Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity.

The transforming growth factor β (TGFβ) stimulates tumor progression and metastasis. Secretion of TGFβ by tumor cells also suppresses an antitumor immune response in which dendritic cells (DCs) play an important role to activate cytotoxic T lymphocytes (CTLs). Herein we report that the small molecule TGFβ signaling inhibitor SB-431542, induces DC maturation in vitro and triggers antitumor activity in vivo. We added SB-431542 to cultures of murine bone-marrow derived DCs (BM-DCs) derived from BALB/c mice and human DCs generated from peripheral monocytes (human DCs) at different concentrations in triplicates and examined expression of co-stimulatory molecules by FACS and production of Interleukin-12 (IL-12) by ELISA. SB induced phenotypic maturation of BM-DCs and human DCs and improved their abilities to produce IL-12 in a dose-dependent manner. SB-431542 also augmented capacity of murine and human DCs to activate naive T cells in allogeneic mixed lymphocyte reaction. Interestingly, SB-431542 augmented the capacity of BM-DCs and human DCs to incorporate FITC-conjugated dextran. Intraperitoneal administration of SB-431542 initiated 3 and 7 days after the implantation of colon-26 cancer cells into the peritoneal cavity of BALB/c mice significantly induced CTL activity against colon-26. We incubated human DCs with SB-431542 and cell lysate of scirrhous gastric cancer cell line OCUM-8, and then examined CTL activities against OCUM-8. CD8 T cells activated by human DCs treated with SB-431542 showed modest augmentation CTL activity against cancer cells. Furthermore, pretreatment of human DCs with SB-431542 upregulated cytotoxic activity against K562 cells, suggesting SB should have potential to activate DCs to natural killer cells. In conclusion, TGFβ receptor I kinase inhibitor such as SB-431542 might induce anti-tumor immune response in immuno-tolerant patients associated with TGFβ activity.

[1]  H. Matsushima,et al.  Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. , 2009, Cancer research.

[2]  B. Clausen,et al.  Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. , 2009, Cancer research.

[3]  J. Hanaoka,et al.  Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. , 2009, Cancer research.

[4]  G. Cheng,et al.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. , 2008, Cancer research.

[5]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[6]  C. Arteaga,et al.  Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. , 2008, Cancer research.

[7]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[8]  A. Villa,et al.  Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. , 2006, Cancer research.

[9]  K. Arihiro,et al.  Tumor-driven evolution of immunosuppressive networks during malignant progression. , 2006, Cancer research.

[10]  Y. Wan,et al.  Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.

[11]  Y. Ogawa,et al.  Discovery of novel immunostimulants by dendritic-cell-based functional screening. , 2005, Blood.

[12]  P. Khaw,et al.  Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. , 2005, Investigative ophthalmology & visual science.

[13]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[14]  A. Palucka,et al.  Dendritic cells as therapeutic vaccines against cancer , 2005, Nature Reviews Immunology.

[15]  M. Yashiro,et al.  Novel models for human scirrhous gastric carcinoma in vivo , 2004, Cancer science.

[16]  M. Weller,et al.  SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.

[17]  S. Adams,et al.  Manipulating dendritic cell biology for the active immunotherapy of cancer. , 2004, Blood.

[18]  A. Prescott,et al.  Enhanced Dendritic Cell Antigen Capture via Toll-Like Receptor-Induced Actin Remodeling , 2004, Science.

[19]  Françoise Gellibert,et al.  Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. , 2004, Journal of medicinal chemistry.

[20]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[21]  H. Tahara,et al.  Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK‐432 combined with prostaglandin E2 , 2003, Cancer science.

[22]  Hiroyuki Aburatani,et al.  SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. , 2003, Cancer research.

[23]  M. Vieth,et al.  Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2003, Journal of medicinal chemistry.

[24]  F. López‐Casillas,et al.  Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. , 2002, Cancer research.

[25]  A. Reith,et al.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. , 2002, Molecular pharmacology.

[26]  A. Thomson,et al.  Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. , 2001, Blood.

[27]  P. Ricciardi-Castagnoli,et al.  Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.

[28]  D. Mercola,et al.  Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Teicher,et al.  TGF-beta in cancer and as a therapeutic target. , 2006, Biochemical pharmacology.

[30]  C. Arteaga.  Inhibition of TGFbeta signaling in cancer therapy. , 2006, Current opinion in genetics & development.

[31]  H. Kawai,et al.  Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. , 2006, Journal of immunology.

[32]  J. Yingling,et al.  Development of TGF-beta signalling inhibitors for cancer therapy. , 2004, Nature reviews. Drug discovery.

[33]  C. Arteaga,et al.  Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. , 2003, Cancer research.

[34]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[35]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.